These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28646641)

  • 41. Management of quality, capacity, and productivity at Merck.
    Nathan J; Venkataraman R
    Hosp Mater Manage Q; 1999 Feb; 20(3):64-9. PubMed ID: 10345635
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Compound scale-up at the discovery-development interface.
    Nikitenko AA
    Curr Opin Drug Discov Devel; 2006 Nov; 9(6):729-40. PubMed ID: 17117683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analyses of direct and indirect impacts of a positive list system on pharmaceutical R&D investments.
    Han E; Kim TH; Jeung MJ; Lee EK
    Clin Ther; 2013 Jul; 35(7):941-9. PubMed ID: 23806327
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overcoming psychological barriers to good discovery decisions.
    Chadwick AT; Segall MD
    Drug Discov Today; 2010 Jul; 15(13-14):561-9. PubMed ID: 20553956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Driving clinical study efficiency by using a productivity breakdown model: comparative evaluation of a global clinical study and a similar Japanese study.
    Takahashi K; Sengoku S; Kimura H
    J Clin Pharm Ther; 2011 Feb; 36(1):87-98. PubMed ID: 21198723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Strategic groups in the biopharmaceutical industry: implications for performance.
    Erden Z; von Krogh G; Nytorp C; Hultberg M
    Drug Discov Today; 2009 Aug; 14(15-16):726-30. PubMed ID: 19416760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Portfolio analysis and R&D decision making.
    Evans R; Hinds S; Hammock D
    Nat Rev Drug Discov; 2009 Mar; 8(3):189-90. PubMed ID: 19182818
    [No Abstract]   [Full Text] [Related]  

  • 48. R&D investments for neglected diseases can be sensitive to the economic goal of pharmaceutical companies.
    Dimitri N
    Drug Discov Today; 2012 Aug; 17(15-16):818-23. PubMed ID: 22414544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lessons learned from candidate drug attrition.
    Empfield JR; Leeson PD
    IDrugs; 2010 Dec; 13(12):869-73. PubMed ID: 21154145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A measure of productivity and innovation in the pharmaceutical industry 2011-2015.
    Harrison R
    Drugs Today (Barc); 2016 Nov; 52(11):627-633. PubMed ID: 28112281
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift.
    Sams-Dodd F
    Drug Discov Today; 2013 Mar; 18(5-6):211-7. PubMed ID: 23131208
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Productivity counts--but the definition is key.
    Mervis J
    Science; 2005 Jul; 309(5735):726. PubMed ID: 16051784
    [No Abstract]   [Full Text] [Related]  

  • 54. Biopharma CRO industry in China: landscape and opportunities.
    Xia C; Gautam A
    Drug Discov Today; 2015 Jul; 20(7):794-8. PubMed ID: 25701282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Contract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation.
    Shi YZ; Hu H; Wang C
    Global Health; 2014 Nov; 10():78. PubMed ID: 25406839
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Productivity growth, case mix and optimal size of hospitals. A 16-year study of the Norwegian hospital sector.
    Anthun KS; Kittelsen SA; Magnussen J
    Health Policy; 2017 Apr; 121(4):418-425. PubMed ID: 28214046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Do cost-sharing and entry deregulation curb pharmaceutical innovation?
    Grossmann V
    J Health Econ; 2013 Sep; 32(5):881-94. PubMed ID: 23896384
    [TBL] [Abstract][Full Text] [Related]  

  • 58. R&D implementation in a department of laboratory medicine and pathology: a systematic review based on pharmaceutical companies.
    Feulefack J; Sergi C
    Glob J Health Sci; 2015 Jan; 7(4):70-82. PubMed ID: 25946935
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Outsourcing drug discovery to India and China: from surviving to thriving.
    Subramaniam S; Dugar S
    Drug Discov Today; 2012 Oct; 17(19-20):1055-8. PubMed ID: 22542471
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel technology to improve pharmaceutical productivity.
    Krebs R
    Curr Opin Drug Discov Devel; 1999 May; 2(3):239-43. PubMed ID: 19649952
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.